Innovent Biologics and Pfizer have entered a global licensing and collaboration agreement to research and develop 12 early-stage cancer medicines, including antibody-drug conjugates and multi-specific antibodies. Innovent will lead initial development through Phase 1, after which Pfizer will take over global development. The companies will co-develop four programs and share costs and profits in the U.S. and Europe, with Innovent retaining rights in Greater China. The deal includes a $650 million upfront payment to Innovent and potential milestone payments up to $9.85 billion, totaling up to $10.5 billion. This partnership aims to accelerate bringing innovative cancer therapies to patients worldwide.
Pfizer will report its Q3 2026 earnings on Nov 3, with investors watching if growth in obesity treatments and other new products can offset declines in COVID-related sales. The company has seen a 25% stock rise this year, driven by strong performance...
Moderna's stock fell 7% after its personalized melanoma vaccine, despite meeting its primary goal in a late-stage trial, showed less impact on distant cancer spread than earlier studies suggested. This has led investors to reassess the commercial pot...
